World Health Organization Issues Alert Over Severe Lack of Obesity Jabs
Fewer than one in 10 individuals that would benefit from obesity jabs like Wegovy can access them, caution the WHO as it issues its initial guidance on the therapies.
Given in excess of 1,000,000,000 individuals worldwide currently living with obesity, it is advocating for more widespread and fairer availability to GLP-1 medication.
Per projections, in excess of 2,000,000,000 could be living with obesity by 2030 if no action is taken.
"Our new guidance recognises that obesity is a chronic disease that can be treated with comprehensive and ongoing treatment," stated WHO director-general Tedros Adhanom Ghebreyesus.
Significant expense, insufficient output, and supply-chain constraints are significant obstacles to universal access to the jabs that can help people shift considerable body mass, explains the body.
Skinny Jab Shortage
Despite the present most favorable scenario, the manufacturing of GLP-1 therapies would only suffice for around 100 million people – under 10% of those who need them, as stated by the WHO.
The advice urges nations and manufacturers to expand access, via approaches like patent sharing.
Exclusive production rights on a key compound – the primary component of Novo Nordisk's Wegovy – is due to expire in a number of nations in 2026.
How Obesity Drugs Function
These medications replicate a biological compound to reduce digestion speed, reduce hunger and increase feelings of fullness so people consume fewer calories.
Individuals usually see weight reduction after several weeks of starting on the weekly injections.
Studies suggests patients may put most of the weight back on a year later of discontinuing the medication, when their normal hunger return.
To be carrying excess weight elevates your chance for developing diseases, like type 2 diabetes, heart disease, stroke, and some cancers.
Obesity affects people in all nations and was responsible for 3.7 million fatalities worldwide in 2024, according to the health agency.
